Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Mucosal Autoimmunity

 

Cecile King's lab is interested mucosal autoimmunity. In type 1 diabetes (T1D), the insulin-producing beta cells of the pancreas are destroyed by selftissue- destructive T cells. These cells express markers that help us to determine, for example, their dependence upon growth factors and where they have been in the body. We are particularly interested in the relationship between the cells that cause T1D and other autoimmune diseases that develop at the mucosal interface between our bodies and the environment. Broad-based suppression is commonly used to treat autoimmune diseases and transplant recipients but it has an obvious drawback since we need a functioning immune system in order to thrive. The aim of our research is to identify target molecules for selective suppression of these self-tissue-destructive cells. 

 

 

Staff

 

Helen McguirePhD Student
Helen McGuire
Christoph JandlVisiting Student
Christoph Jandl
Elisabeth MalleVisiting Student
Elisabeth Malle
Visiting Student
Sylvie Denoyelle

 

 

 

News

 

The genetic fuse that may ignite Type 1 diabetes

MEDIA RELEASE: 20 Oct 2009
Garvan scientists have discovered that a tiny genetic irregularity, which boosts the expression of a key gene, may lead to the development of Type 1 diabetes. While there is no cure yet, prevention therapies are on the horizon, making the development of reliable screening tools critical. And that's where the current finding has promise.
 
 

Garvan immunology students win main prizes at ASI conference

19 Dec 2008
For the second year in a row, a PhD student from Garvan has won the very prestigious New Investigator Award at the annual Australasian Society for Immunology (ASI) conference, held last week in Canberra. The 2008 winner is Alexis Vogelzang.
 
 

Immunology in the very blood of Castle Harlan award winner

31 Oct 2008
Helen McGuire has received the $10,000 USD Castle Harlan award for being the most outstanding early career PhD student at the Garvan Institute in 2008. Castle Harlan is a distinguished and philanthropic US-based private equity firm that wishes to support the kind of medical research being undertaken at Garvan.
 
 

Personal tools